Clinical Trial

UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases

Name: UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases — clinical trial record (NCT06978738)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases.

Trial Details

NCT Number	NCT06978738
Lead Sponsor	Changzhou No.2 People's Hospital
Conditions	Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia, Myasthenia Gravis, Systemic Sclerosis, ANCA-Associated Vasculitis, Inflammatory Myopathy, IgG4-RD
Enrollment	18 participants
Start Date	2025-05
Primary Completion	2027-05 (estimated)
Study Completion	2028-11 (estimated)
Updated on ClinicalTrials.gov	2025-05-18